Epidemiology of hepatitis D virus infection in Europe: Is it vanishing?

• Published in: Journal of Viral Hepatitis
• Main Authors: Demirel, Aslıhan, Uraz, Suleyman, Deniz, Zeynep, Daglilar, Ebubekir, Basar, Omer, Tahan, Veysel, Ozaras, Resat
• Format: Article in Journal/Newspaper
• Language: English
• Published: Wiley 2023
• Subjects: Greenland; Norway
• Online Access: http://dx.doi.org/10.1111/jvh.13899; https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.13899

Abstract Co‐infection with hepatitis delta virus (HDV) is a challenging health care problem worldwide, estimated to occur in approximately 5%–10% of patients with chronic hepatitis B virus (HBV) infection. While HBV prevalence is decreasing globally, the prevalence of HDV infection is rising in some parts mainly due to injection drug use, sexual transmission and immigration from high endemicity areas. Eastern Europe and the Mediterranean are among the regions with high rates of endemicity for HDV and the immigration from high endemicity areas to Central and Western Europe has changed the HDV epidemiology. We aimed to review the prevalence of HDV infection in Europe. A paucity of publication appears in many European countries. Prevalence studies from some countries are old dated and some other countries did not report any prevalence studies. The studies are accumulated in few countries. Anti‐HDV prevalence is high in Greenland, Norway, Romania, Sweden and Italy. Belgium, France, Germany, Spain, Switzerland, Turkey and United Kingdom reported decreasing prevalences. Among cirrhotic HBV patients, Germany, Italy and Turkey reported higher rates of HDV. The studies including centres across the Europe reported that HIV‐HBV coinfected individuals have higher prevalence of HDV infection. The immigrants contribute the HDV infection burden in Greece, Italy, and Spain in an increasing rate. Previous studies revealed extremely high rates of HDV infection in Germany, Greece, Italy and Sweden. The studies report a remarkably high prevalence of hepatitis delta among HIV/HBV‐coinfected individuals, individuals who inject drugs, immigrants and severe HBV infected patients across Europe. The HDV infection burden still appears to be significant. In the lack of an effective HDV therapy, prevention strategies and active screening of HBV/HDV appear as the most critical interventions for reducing the burden of liver disease related to HDV infection in Europe.